Taysha Gene Therapies (TSHA) Operating Margin (2023 - 2025)

Taysha Gene Therapies has disclosed Operating Margin across 3 years of filings, most recently posting 2334.98% for Q4 2025.

• Operating Margin for Q4 2025 came in at 2334.98%, down 134923.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 4145.18% (down 291941.0% YoY), and the FY2025 annual result was 2009.05%, down 91150.0% from the prior year.
• Operating Margin came in at 2334.98% for Q4 2025 at Taysha Gene Therapies, down from 1347.08% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 342.39% in Q3 2023 to a low of 2334.98% in Q4 2025.
• The 3-year median for Operating Margin is 976.37% (2023), against an average of 1072.44%.
• Peak annual rise in Operating Margin reached 56830 bps in 2025, while the deepest fall reached 134923 bps in 2025.
• Taysha Gene Therapies' Operating Margin stood at 450.78% in 2023, then sank by 119 bps to 985.76% in 2024, then tumbled by 137 bps to 2334.98% in 2025.
• The last three Operating Margin figures came in at 2334.98% (Q4 2025), 1347.08% (Q2 2025), and 930.54% (Q1 2025), per Business Quant data.